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Adapted ketogenic diet (AKD) and caloric restriction (CR) have been suggested as alternative
therapeutic strategies for multiple sclerosis (MS), but information on their impact on neuro-
axonal damage is lacking. Thus, we explored the impact of diets on serum neurofilament light
chain (sNfL) levels in patients with relapsing-remitting MS.
Methods
We retrospectively evaluated a prospective randomized controlled trial of 60 patients with MS
who were on a common diet or ketogenic diet or fasting. We examined sNfL levels of 40
participants at baseline and at the end of the study after 6 months using single molecule array
assay.
Results
sNfL levels were investigated in 9 controls, 14 participants on CR, and 17 participants on AKD.
Correlation analysis showed an association of sNfL with age and disease duration; an associ-
ation was also found between sNfL and the Multiple Sclerosis Functional Composite. AKD
significantly reduced sNfL levels at 6 months compared with the common diet group (p =
0.001).
Discussion
For clinical or study use, consider that AKD may incline sNfL levels independent of relapse
activity up to 3 months after initiation. At 6 months, AKD, which complements current
therapies, reduced sNfL levels, therefore suggesting potential neuroprotective effects in MS. A
single cycle of seven-day fasting did not affect sNfL. AKD may be an addition to the arma-
mentarium to help clinicians support patients with MS in a personalized manner with tailored
diet strategies.
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Research Center (ECRC) A Joint Cooperation of Charité Medical Faculty and Max-Delbrueck-Center for Molecular Medicine (MDC) (M.B.).
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.
The Article Processing Charge was funded by the authors.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading
and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. 1
In multiple sclerosis (MS), effective therapeutic strategies and
sensitive biomarkers to evaluate drug efficacy anddisease course are
urgently needed. Serum neurofilament light chain protein (sNfL)
has recently been suggested as a promising candidate for a reliable,
easy-to-use biomarker of neuroaxonal damage that accurately de-
tects changes over both long and short time intervals inMS.1,2 After
axonal injury, NfL is elevated in both the CSF and in the peripheral
blood, where it can bemeasured by highly sensitive singlemolecule
assays (SiMoA).3,4 Studies have suggested a possible role of caloric
restriction (CR) and adapted ketogenic diet (AKD) on neuro-
inflammation in MS and other neurologic disorders.5-7 The ob-
served diet-induced improvement of neuronal resistance and
axonal survival are clearly neuroprotective, but the underlying
mechanisms remain elusive.5,8 In the present study, we investigated
whether AKD and CR in comparison to common diet (CD) may
affect neurodegeneration as measured by sNfL levels in MS.
Methods
Clinical Trial Design, Patients, Study Setting,
Interventions, and Primary Outcome
All study details were described previously6,7,9 and are presented
in eMethods, links.lww.com/NXI/A653. This study was a three-
armed parallel group, single-centered, controlled and random-
ized clinical trial. This study was registered at clinicaltrials.gov as
NCT01538355.
Outcome Measure
The sNfL concentration of 40 patients was quantified in 2020/
2021.
sNfL Measurements
We applied the same method as described recently3 and
presented in eMethods, links.lww.com/NXI/A653. In brief,
sNfL was measured in several rounds by SiMoA HD-1
(Quanterix) using the NF-Light Advantage Kit (Quanterix)
from the same batch according to the manufacturer’s in-
structions. sNfL analysis was performed in a blinded fashion
without clinical information about patients.
Control Diet
Patients on CD met the criteria of a common diet in the




As previously described, a single cycle of 7-day CR (200–350
kcal/d) was performed at study outset; a 3-day stepwise
reintroduction to an isocaloric common diet was performed
starting on day 8.6
Adapted Ketogenic Diet
Patients followed an AKD for 6months from study outset. We
recommended an average daily intake of <50 g carbohydrates,
> 160 g fat (omega 6 vs omega 3 ratio 2:1), and average
protein intake ≤100 g per day. Compliance during CR and
AKD was monitored via ketosis self-measured in blood and
urine.
Standard Protocol Approvals, Registrations,
and Patient Consents
This study was approved by the local ethics committee in
the frame of the IGEL study (ethics no. EA1/105/11). All
patients included in this study signed specific informed
consent.
Statistical Analysis
We used analyses of covariance to test for group differences
using sNfL baseline data, number of clinical relapses over the
course of the study, and body mass index (BMI) as covariates.
The Wilcoxon matched-pairs signed-rank test analysis was
used for intragroup statistics.
Data Availability
Anonymized data will be made available on request from any
qualified investigator.
Results
Situation Before Dietary Intervention
Baseline Intergroup Comparison: No Differences in
Outcome
Patient demographics did not differ significantly when the
different intervention groups were compared (Table 1). The
use of the disease-modifying therapy (DMT) glatiramer ac-
etate was significantly different between the groups, but this
is clinically not relevant. sNfL levels did not differ signifi-
cantly between the 3 groups before dietary interventions.
These data indicate that the dietary habits of the patients
involved in the study did not influence the sNfL concen-
tration at baseline.
Next, we correlated disease-related and participant-reported
parameters across all groups involving all individuals of all
experimental groups. We found a significant association
between sNfL and age (r = 0.347, p < 0.05) and disease
duration (r = 0.313, p < 0.05) confirming observations of
Glossary
AKD = adapted ketogenic diet; BMI = body mass index; CD = common diet; CR = caloric restriction; DMT = disease-
modifying therapy;MS =multiple sclerosis;MSFC =Multiple Sclerosis Functional Composite; PASAT = Paced Auditory Serial
Addition Test; SiMoA = single molecule assay; sNfL = serum neurofilament light chain.
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other groups. Moreover, we observed a significant inverse
correlation between sNfL and the Multiple Sclerosis Func-
tional Composite 2 and 3 (MSFC 2 + 3) (r = -0.298, p <
0.05; r = -0.317, p < 0.05) and the Paced Auditory Serial
Addition Test 3 (r = −0.298, p < 0.005) (Table 1;
eFigure 1–eFigure 5, links.lww.com/NXI/A653). Of in-
terest, sNfL levels did not significantly correlate with BMI or
with the clinically meaningful neurologic measure Expanded
Disability Status Scale. There was also no correlation with
the self-report questionnaires Multiple Sclerosis Quality of
Life-54 (MS-54), Fatigue Severity Scale, Modified Fatigue
Impact Scale, and Beck Depression Inventory.
NfL Alterations as Consequence of
Dietary Intervention
Intragroup Comparison: AKD Induced Significant
Reductions in sNfL Within 6 months
In the AKD group (n = 17), we found a significant decrease
in the sNfL level from 8.5 at baseline (no dietary intervention)
to 7.1 pg/mL (mean difference -1.307; 95% CI -2.256 to
-0.357; p < 0.05) at the end of the study after 6 months. The
analysis of the CR group (n = 14) and CD group (n = 9)
showed similar sNfL levels at baseline and at the final visit
(Figure 1 and eTable 1, links.lww.com/NXI/A653).
Table 1 Baseline Characteristics and Associations
Baseline characteristics CD (n = 9) SD IQR CR (n = 14) SD IQR AKD (n = 17) SD IQR ap Value
Age, y 50 6 45.71 10.5 43.06 9.7 0.3
Sex, F/M 6/3 (67/33) 12/2 (86/14) 13/4 (76/24) 0.6
Expanded Disability Status Scale score 3.0 1.75–4 3.5 2.4–4.0 3.0 2.5–3.5 0.5
Disease duration, y 11.0 10.3 10.6 7.8 7.1 5.3 0.3
Relapse rate 12 mo prior study outset 0.22 0.4 0.26 0.4 0.47 0.5 0.3
No immune modulating drugs 1 (11) 2 (14) 5 (29) 0.4
Glatiramer acetate 7 (78) 4 (29) 4 (24) 0.02
Interferon beta 0 6 (43) 4 (24) 0.07
Fingolimod 0 1 (7) 3 (18) 0.3
Natalizumab 1 (11) 1 (7) 1 (6) 0.9
BMI, kg/m2 26.6 7.3 26.8 4.7 26.3 4.9 0.7
Percent body fat 36.2 11.3 37.1 9.6 36.3 9.5 0.9
Fasting blood sugar, mmol/L 4.6 0.5 4.5 0.8 4.4 0.5 0.9
β-hydroxybutyrate, μmol/L 105.9 72.1 111.3 118.3 112.4 100.5 0.6
MSFC-3 0.17 0.7 −0.13 0.7 −0.02 0.9 0.3
MSFC-2 0.34 0.8 −0.08 0.6 −0.14 0.9 0.05
PASAT-3 49.56 11.3 40.5 12.5 46.79 10 0.09
sNfL, ng/mL 8.9 3.6 10.3 3.6 8.5 2.0 0.3
Associations Age Disease Duration PASAT-3 MSFC-3 MSFC-2 BMI EDSS score MS-54 PH MS-54 MH FSS score MFIS score BDI
sNfL
Spearman rho 0.347 0.313 −0.406 −0.317 −0.298 −0.133 0.013 0.099 0.031 −0.122 −0.109 −0.186
p (2 tailed) 0.01 0.02 0.004 0.03 0.04 0.41 0.93 0.55 0.84 0.41 0.47 0.22
Abbreviations: AKD = adapted ketogenic diet; BMI = body mass index; CD = common diet; CR = caloric restriction diet; MSFC = Multiple Sclerosis Functional
Composite; PASAT = Paced Auditory Serial Addition Test; sNfL = serum neurofilament light chain.
Baseline intergroup analysis: data are presented asmean (SD), number (%), ormedian (interquartile range, IQR), as appropriate. Baseline data were available
for 40 patients.
a Nonparametric Kruskal-Wallis test to compare between all 3 groups.
Abbreviations: BDI = Beck Depression Inventory; BMI = body mass index; EDSS = Expanded Disability Status Scale; FSS = Fatigue Severity Scale; MFIS =
Modified Fatigue Impact Scale; MSFC = Multiple Sclerosis Functional Composite; PASAT = Paced Auditory Serial Addition Test; sNfL = serum neurofilament
light chain.
Baseline cross-group correlation: Analysis between sNfL and disease-related or subject-reported parameters.
Multiple Sclerosis Quality of Life-54 physical/mental health (MS-54 PH/MH).
Bold indicates significance, defined as p < 0.05.
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Intergroup Comparison: AKD Lowers sNfL Levels in
Comparison to Common Diet
We used baseline sNfL concentrations, relapse rate, and
D-BMI as covariates for between-group evaluation. At the end
of the study, we observed a significant decline in sNfL levels
(Figure 2 and eTable 2, links.lww.com/NXI/A653) when we
compared AKD with CD (adjusted difference -2.145 ± 0.615;
95% CI -3.393 to -0.897; p = 0.001) after 6 months. We did
not find a difference in sNfL levels between CR and CD
groups at month 3 (adjusted difference 1.24 ± 1.71; 95% CI
-2.236 to 4.716; p = 0.682).
Relapse Rate and sNfL Over the Course of
the Study
Twelve months prior study outset, the relapse rate did not
differ significantly between the groups (Table 1). In the
course of the study, 3 relapses in the CD group, 2 relapses in
the CR group, and 1 relapse in the AKD group were
reported. When analyzing sNfL levels at month 3, we
detected a significant increase over all groups (eFigure 6 and
eTable 1, links.lww.com/NXI/A653). After excluding
samples from patients with relapse activity, the sNfL levels of
the AKD group remained elevated (eFigure 7, links.lww.
com/NXI/A653).
Discussion
In this randomized controlled trial we investigated the impact
of intermittent fasting/CR and AKD on sNfL levels in pa-
tients with MS. In the examined groups, sNfL levels were
comparable with previous studies using the same methodol-
ogy supporting the reliability of our results and of the applied
assay analysis method.3 However, earlier studies have de-
scribed higher sNfL levels due to various internal protocols, as
recently discussed.10
This setting not only allowed assessment of the relative effects
of AKD treatment vs common diet and 7-day fasting in a
parallel randomized design but also provided the opportunity
to study the relation of sNfL as a specific marker of neuro-
axonal damage with other anthropometric, clinical, and
Figure 1 Intra-Group Comparison – Adapted Ketogenic Diet Lowers the SerumConcentration ofNeurofilament Light Chain II
Alterations of serum neurofilament light chain (sNfL) levels
induced by caloric restriction and adapted ketogenic diet.
Data representmean ± standard error of themean andwere
measured at baseline and retested at 6 months for all
groups. p values indicate Wilcoxon matched-pairs signed
rank test analysis, *p < 0.05.
Figure 2 Comparison of sNfL Levels in Patients With MS on Adapted Ketogenic Diet With Common Diet
After 6 months of adapted ketogenic diet, the serum neu-
rofilament light chain (sNfL) concentration declined signifi-
cantly compared to the common diet group. Data were
measured at baseline and retested at 6 months. Data rep-
resent mean ± standard error of the mean. **p < 0.01,
analysis of covariance (ANCOVA) adjusted for relapse rate,
BMI and baseline dependencies.
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patient-reported measures of disease activity and severity
obtained under good clinical practice conditions.
Baseline characteristics of patients included in this analysis do
not suggest any relevant selection bias. sNfL concentrations in
patients were similar over all groups at baseline. sNfL levels at
baseline were correlated with functional markers of disease
activity (e.g., PASAT and MSFC) confirming recent re-
ports.3 Although diet as an environmental factor has been
acknowledged in MS, its precise role in the pathogenesis of
MS is still far from clear. Moreover, dietary interventions
are rapidly gaining popularity within the MS community,
but little is known about their safety. AKD and CR have
been suggested to induce autophagy and to improve gut
microbiota, redox status, and regulatory T cells in a variety
of diseases.5,7,9,11,12
It has previously been shown that NfL levels, as a neuro-
axonal integrity parameter and marker of treatment re-
sponse, decrease after initiation of DMTs3 In line with this,
our results indicate that AKD may influence sNfL levels in
patients with MS. More studies are necessary to evaluate
the longitudinal impact of repeated fasting cycles on sNfL
levels in MS.
Our analysis reflects a significant relationship between AKD
and declining sNfL levels at 6months. This suggests that AKD
may benefit the course of disease in MS. However, more
comprehensive studies with an expanded time span are
needed to examine whether effects could relate to the diet
itself rather than its impact on MS. The limitations of our
study include its short observation time of 6 months, MRI was
not performed and a limited power, due to a relatively small
number of participants (n = 40 analyzed patients). It should
also be noted that the extent of variation indicating a clinically
meaningful change in longitudinal sNfL measurements has
not yet been defined. However, we also found increased sNfL
levels in the AKD group, independent of relapse activity at
month 3. Our observation could be due to autophagy of which
AKD and CR are strong inductors.11,12 Of interest, it was
reported that autophagy promotes intracellular degradation of
cytoskeleton but also seems to be essential for the survival of
neuronal cells.13 However, it is likely that release of degra-
dation products would increase sNfL levels extracellularly
(and thus in serum) at least in the short term—thus our
results would be consistent with the latter results of different
groups.
AKD needs more time than CR to activate homeostatic
processes, e.g., autophagy, due to the process of keto-
adaptation and slower/lower ketone body excess. This may
explain why we did not detect an increase in sNfL in the CR
group at month 3.
Overall, our study suggests that an AKD offers an avenue to
impact sNfL levels, which seems to be a promising biomarker
in neuroinflammatory diseases, supporting the use of dietary
interventions as a treatment tool for MS. These findings are of
urgent medical interest because such dietetic strategies exhibit
few unwanted side effects.
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